Anticoagulation Management in Patients Receiving Warfarin at Private Cardiac Centers in Addis Ababa, Ethiopia

References

• Albabtain MA, Alharthi MM, Dagriri K., et al. Assessment of the quality of anticoagulation management with warfarin in a tertiary care center. Saudi Med J. 2020;41(11):1245–1251. doi:10.15537/smj.2020.11.25456
   PubMed Web of Science ®Google Scholar
• Laäs DJ, Naidoo M. An evaluation of warfarin use at an urban district-level hospital in KwaZulu-Natal Province, South Africa. South Af Med J. 2018;108(12):1046–1050. doi:10.7196/SAMJ.2018.v108i12.13256
   PubMed Web of Science ®Google Scholar
• Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for the management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018;2(22):3257–3291. doi:10.1182/bloodadvances.2018024893
   PubMed Web of Science ®Google Scholar
• Zeitler EP, Eapen ZJ, Clinical D, Nc D. Anticoagulation in heart failure: a review. J Atrial Fibrillation. 2015;8(1). doi:10.4022/jafib.1250
   PubMedGoogle Scholar
• Di MA, Frigerio B, Spadarella G, et al. Old and new oral anticoagulants: food, herbal medicines and drug interactions. Blood Rev. 2017;31(4):193. doi:10.1016/j.blre.2017.02.001
   PubMed Web of Science ®Google Scholar
• Fibrillation A, Nelson WW, Choi JC, et al. Impact of co-morbidities and patient characteristics on international normalized ratio control over time in patients with nonvalvular. Am J Cardiol. 2013;112(4):509–512. doi:10.1016/j.amjcard.2013.04.013
   PubMed Web of Science ®Google Scholar
• Karuri S, Nyamu D, Opanga S, Menge T. Factors associated with time in therapeutic range among patients on oral anticoagulation therapy in a tertiary teaching and referral hospital in Kenya. East Cent Af J Pharm Sci. 2019;22(3):85–95.
   Google Scholar
• Alghadeeer S, Alzahrani AA, Alalayet WY, Alkharashi AA, Alarifi MN. Anticoagulation control of warfarin in pharmacist-led clinics versus physician-led clinics: a prospective observational study. Risk Manag Healthc Policy. 2020;13:1175–1179. doi:10.2147/RMHP.S248222
   PubMed Web of Science ®Google Scholar
• Mwita JC, Francis JM, Oyekunle AA, Gaenamong M, Goepamang M, Magafu MGMD. Quality of anticoagulation with warfarin at a tertiary hospital in Botswana. Clin Appl Thrombosis Hemostasis. 2018;24(4):596–601. doi:10.1177/1076029617747413
   PubMed Web of Science ®Google Scholar
• Gabriel P, De BM, Sznejder H, et al. Anticoagulation therapy in patients with non-valvular atrial fibrillation in a private setting in Brazil: a real-world study. Arq Bras Cardiol. 2020;114:457.
   PubMed Web of Science ®Google Scholar
• Farsad B, Abbasinazari M, Dabagh A, Bakshandeh H. Evaluation of time in therapeutic range (TTR) in patients with non-valvular atrial fibrillation receiving treatment with warfarin in Tehran, Iran: a cross-sectional study. J Clin Diagnostic. 2016;20(9):20–22. doi:10.7860/JCDR/2016/21955.8457
   Google Scholar
• Prinsloo DN, Gould TJ, Viljoen CA, Basera W, Ntsekhe M. International normalised ratio control in a non-metropolitan setting in Western Cape Province, South Africa. South African Med J. 2021;111(4):355–360. doi:10.7196/SAMJ.2021.v111i4.15171
   PubMed Web of Science ®Google Scholar
• Pastori D, Farcomeni A, Saliola M, Del F, Pignatelli P. Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation. Eur J Intern Med. 2018;1. doi:10.1016/j.ejim.2018.04.007
   Web of Science ®Google Scholar
• Ntlokotsi S, Moshesh MF, Mntla P, Towobola OA, Mogale MA. Optimum INR intensity and therapeutic INR control in patients with mechanical heart valve prosthesis on warfarin oral anticoagulation at Dr George Mukhari academic hospital: a three-year retrospective study. South African Family. 2018;60(6):192–196.
   Web of Science ®Google Scholar
• Caldeira D, Cruz I, Morgado G, et al. Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study. Revista Portuguesa de Cardiologia. 2014;34(1):1–5. doi:10.1016/j.repc.2014.08.005
   Google Scholar
• Gateman D, Trojnar ME, Agarwal G, Gateman D, Trojnar ME, Agarwal G. Time in therapeutic range Un RIN dans la fourchette thérapeutique. Canadian Family Phys. 2017;63:425–431.
   PubMed Web of Science ®Google Scholar
• Chan P. Time in therapeutic range and percentage of inrs in therapeutic range as measure of quality of anticoagulation control in atrial fibrillation patients. Can J Cardiol. 2015;32(10):1247.e23–1247.e28. doi:10.1016/j.cjca.2015.10.029
   PubMed Web of Science ®Google Scholar
• Han SY, Palmeri ST, Broderick SH, et al. Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting. J Electrocardiol. 2013;46(1):45–50. doi:10.1016/j.jelectrocard.2012.08.011
   PubMed Web of Science ®Google Scholar
• Botsile E, Mwita JC. Incidence and risk factors for thromboembolism and major bleeding in patients with mechanical heart valves: a tertiary hospital-based study in Botswana. Cardiovasc J Afr. 2020;31(4):185–189. doi:10.5830/CVJA-2020-006
   PubMed Web of Science ®Google Scholar
• Jonkman LJ, Gwanyanya MP, Kakololo MN, Verbeeck RK, Singu BS. Assessment of anticoagulation management in outpatients attending a warfarin clinic in Windhoek, Namibia. Drugs Ther Perspect. 2019;35(7):341–346. doi:10.1007/s40267-019-00630-y
   Google Scholar
• Ugur A, Turk O, Tuncer E, Alioglu E, Yuksel K. Evaluation of the impact of warfarin s time-in-therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the Observational, Prospective WATER Registry. Cardiology J. 2015;1:548. doi:10.5603/CJ.a2015.0035
   Google Scholar
• Quinn LM, Richardson R, Cameron KJ, Battistella M. Evaluating time in therapeutic range for hemodialysis patients taking warfarin. Clin Nephrol. 2015;83(2):80–85. doi:10.5414/CN108400
   PubMed Web of Science ®Google Scholar
• de Castro KP. A Patient decision aid for anticoagulation therapy in patients with nonvalvular atrial fibrillation: development and pilot study. JMIR Cardio. 2021;5(2):e23464. doi:10.2196/23464
   PubMedGoogle Scholar
• Sonuga BO, Hellenberg DA, Cupido CS, Jaeger C. Profile and anticoagulation outcomes of patients on warfarin therapy in an urban hospital in Cape Town, South Africa. Af J Prim Heal Care Fam Med. 2016;8(1):e1–e8. doi:10.4102/phcfm.v8i1.1032
   PubMedGoogle Scholar
• Ouali S, Ben Halima A, Chabrak S, et al. Epidemiological characteristics, management, and outcomes of atrial fibrillation in Tunisia: results from the National Tunisian Registry of Atrial Fibrillation (NATURE-AF). Clin Cardiol. 2021;44(4):501–510. doi:10.1002/clc.23558
   PubMed Web of Science ®Google Scholar
• Mariita K, Nyamu DG, Maina CK, Karimi PN. Patient factors impacting on oral anticoagulation therapy among adult outpatients in a Kenyan referral hospital. Af J Pharmacol Therapeutics. 2016;1:548.
   Google Scholar
• Sadhabariss D, Brown SL. Warfarin: time in therapeutic range, a single centre study on patients using warfarin for stroke prevention in non-valvular atrial fibrillation and prosthetic heart valves. SA Hear. 2021;18(1):28–38. doi:10.24170/18-1-4771
   Google Scholar
• Fenta TG, Assefa T, Alemayehu B. Quality of anticoagulation management with warfarin among outpatients in a tertiary hospital in Addis Ababa, Ethiopia: a retrospective cross-sectional study. Af J Pharmacol. 2017:1–7. DOI:10.1186/s12913-017-2330-0
   Google Scholar
• Yimer NS, Abiye AA, Hussen SU, Tadesse TA. Anticoagulation control, outcomes, and associated factors in patients with atrial fibrillation receiving warfarin at tertiary care hospital in Ethiopia. Clin Appl Thromb. 2021;27:107602962110497. doi:10.1177/10760296211049786
   Web of Science ®Google Scholar
• Liyew Z, Tadesse A, Bekele N, Tsegaye T. Evaluation of anticoagulation outcome among patients taking warfarin: a single-center experience, Northwest Ethiopia. Res Sq. 2017;20–25.
   Google Scholar
• Masresha N, Muche EA, Atnafu A, Abdela O. Evaluation of warfarin anticoagulation at University of Gondar comprehensive specialized. J Blood Med. 2021;12:189–195. doi:10.2147/JBM.S282948
   PubMed Web of Science ®Google Scholar
• Pourhoseingholi MA, Vahedi M, Rahimzadeh M. Sample size calculation in medical studies. Gastroenterol Hepatol Bed Bench. 2013;6(1):14–17.
   PubMedGoogle Scholar
• Masresha N, Muche EA, Atnafu A, Abdela O. Evaluation of warfarin anticoagulation at University of Gondar comprehensive specialized hospital, north-west Ethiopia. J Blood Med. 2021;12:189–195. doi:10.2147/JBM.S282948
   PubMed Web of Science ®Google Scholar
• Rosendaal FR, Cannegieter SC, Van der Meer FJM, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–239. doi:10.1055/s-0038-1651587
   PubMed Web of Science ®Google Scholar
• Thomson Micromedex. Micromedex Healthcare Series [Intranet Database]. Version 5.1. Greenwood Village, Colo: Thomson Micromedex; 2005.
   Google Scholar
• Karuri WS. Quality of Oral Anticoagulation Management Among Patients on Follow Up At Kenyatta National Hospital. University of Nairobi; 2016.
   Google Scholar
• Liyew Z. Evaluation of Anticoagulation Outcome among Patients Taking Warfarin: a Single-Center Experience, Northwest Ethiopia. Adv Hematol. 2021;2021:5489.
   Google Scholar
• Fenta TG, Assefa T, Alemayehu B. Quality of anticoagulation management with warfarin among outpatients in a tertiary hospital in Addis Ababa, Ethiopia: a retrospective cross-sectional study. BMC Health Serv Res. 2017;17(1):1–7. doi:10.1186/s12913-017-2330-0
   PubMed Web of Science ®Google Scholar
• Ciurus T, Cichocka-Radwan A, Lelonek M. Factors affecting the quality of anticoagulation with warfarin: experience of one cardiac centre. Kardiochirurgia I Torakochirurgia Pol. 2015;12(4):334–340. doi:10.5114/kitp.2015.56784
   PubMedGoogle Scholar
• McAlister FA, Wiebe N, Hemmelgarn BR. Time in therapeutic range and stability over time for warfarin users in clinical practice: a retrospective cohort study using linked routinely collected health data in Alberta, Canada. BMJ Open. 2018;8(1):1–9. doi:10.1136/bmjopen-2017-016980
   Web of Science ®Google Scholar
• Yimer NS, Abiye AA, Hussen SU, Tadesse TA. Anticoagulation control, outcomes, and associated factors in patients with atrial fibrillation receiving warfarin at tertiary care hospital in Ethiopia. Clin Appl Thromb. 2021;2:27. doi:10.1177/10760296211049786
   Google Scholar
• Health P, Setting C. The quality of anticoagulation therapy among warfarin-treated patients with atrial fibrillation in a primary health care setting. Medicina. 2019;55:1–11. doi:10.3390/medicina55010015
   Google Scholar
• Lertsanguansinchai P, Huntrakul A, Rungpradubvong V. Factors predicting poor anticoagulant control on warfarin in a Thai population with non ‑ valvular atrial fibrillation (NVAF): the ACAChE score. Int J Arrhythmia. 2021;22(1). doi:10.1186/s42444-021-00038-8
   Google Scholar
• Sa MA. Quality of vitamin K antagonist anticoagulation in spain: prevalence of poor control and associated factors. Revista Española de Cardiología. 2015;68(9):761–768.
   PubMed Web of Science ®Google Scholar
• Hakeem H. Evaluation of quality of warfarin therapy by assessing patient s time in therapeutic range at a tertiary care hospital in Pakistan. JPMA. 2018;68(9):1339–1344.
   Google Scholar
• Mwita JC, Francis JM, Oyekunle AA, Gaenamong M, Goepamang M, Magafu MGMD. Quality of anticoagulation with warfarin at a tertiary hospital in Botswana. Clin Applied Thromb. 2017;1:596. doi:10.1177/1076029617747413
   Google Scholar
• Task A, Members F, Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the diagnosis and management of atrial fibrillation of the Europe. Clin Applied Thromb. 2020;373–498.
   Google Scholar
• McAuliffe GN, De Silva F, Upton A, Chan G. International normalised ratio monitoring in the community populations of the Auckland and Northland regions of New Zealand: time in therapeutic range and frequency of testing. Int Med J. 2018;48(12):1487–1491. doi:10.1111/imj.14032
   Google Scholar
• de Barros e Silva PGM, Sznejder H, Vasconcellos R, et al. Anticoagulation therapy in patients with non-valvular atrial fibrillation in a private setting in Brazil: a real-world study. Arq Bras Cardiol. 2020;114(3):457–466. doi:10.36660/abc.20180076
   PubMed Web of Science ®Google Scholar
• Teklay G, Shiferaw N, Legesse B, Bekele ML. Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational study. Thrombosis J. 2014;12(1):1–8. doi:10.1186/1477-9560-12-20
   PubMedGoogle Scholar
• Tadesse TA, Woldu MA. Prevalence of warfarin drug interaction and warfarin education practice in outpatient setups of university teaching hospital. J Basic Clin Pharm. 2018;262–266.
   Google Scholar
• Liyew Z, Tadesse A, Bekele N, Tsegaye T. Evaluation of anticoagulation control among patients taking warfarin in University of Gondar Hospital, Northwest Ethiopia. Adv Hematol. 2021;2021:1–8. doi:10.1155/2021/7530997
   Google Scholar
• Feungfu L. Evaluation of time in therapeutic range among patients receiving warfarin therapy: a retrospective cohort study at one private hospital in Thailand. Int J Med. 2021;48(2):107–114.
   Google Scholar